Edition:
United States

Retrophin Inc (RTRX.O)

RTRX.O on Consolidated Issue listed on NASDAQ Global Market

21.25USD
22 Jul 2019
Change (% chg)

-- (--)
Prev Close
$21.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
404,957
52-wk High
$33.00
52-wk Low
$17.53

About

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $948.89
Shares Outstanding(Mil.): 38.39
Dividend: --
Yield (%): --

Financials

  RTRX.O Industry Sector
P/E (TTM): -- 69.41 32.67
EPS (TTM): -1.86 -- --
ROI: -15.89 8.94 14.49
ROE: -22.95 10.07 15.79

'Pharma Bro' Martin Shkreli to stay behind bars, loses appeal of conviction

NEW YORK A federal appeals court upheld the conviction and seven-year prison term of Martin Shkreli, the pharmaceutical executive known as "Pharma Bro," for defrauding investors in his hedge funds and conspiring to manipulate the stock of Retrophin Inc, a biotechnology company he ran.

Jul 18 2019

UPDATE 2-'Pharma Bro' Martin Shkreli to stay behind bars, loses appeal of conviction

NEW YORK, July 18 A federal appeals court upheld the conviction and seven-year prison term of Martin Shkreli, the pharmaceutical executive known as "Pharma Bro," for defrauding investors in his hedge funds and conspiring to manipulate the stock of Retrophin Inc, a biotechnology company he ran.

Jul 18 2019

Martin Shkreli settles all litigation with his former company Retrophin

NEW YORK Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, has settled all outstanding disputes with Retrophin Inc, the biopharmaceutical company he founded in 2011 and which ousted him three years later.

Jun 20 2019

Martin Shkreli settles all litigation with his former company Retrophin

NEW YORK, June 20 Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, has settled all outstanding disputes with Retrophin Inc , the biopharmaceutical company he founded in 2011 and which ousted him three years later.

Jun 20 2019

From prison, 'Pharma Bro' Martin Shkreli sues ex-colleagues for $30 million

NEW YORK Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, on Friday sued three former colleagues at Retrophin Inc for more than $30 million, saying they illegally ousted him from that company in 2014.

May 31 2019

From prison, 'Pharma Bro' Martin Shkreli sues ex-colleagues for $30 mln

NEW YORK, May 31 Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, on Friday sued three former colleagues at Retrophin Inc for more than $30 million, saying they illegally ousted him from that company in 2014.

May 31 2019

Earnings vs. Estimates